Comparison of LimpiAD Cream 2.5% Plus Versus Vehicle and an Emollient in Patients With Atopic Dermatitis

Inclusion criteria Subjects of both sexes, with age ranging between 2 years and 16 years, Caucasian and in good health, whose parents/tutors provided a written and signed informed consent for their participation in the study shall be enrolled. In particular, as regards parents/tutors: * both parents/tutors, in case of joint custody, should provide a written and signed informed consent for the participation of the child in the study, according to the instructions provided by the Investigators. * they should accept to bring the child to the clinical trial facility on predefined visit days, according to the instructions provided by the Investigators; * they should be willing and able to follow the trial requirements provided by the Investigators. Inclusion criteria provide that: * Symptoms and signs compatible with a clinical diagnosis of Atopic Dermatitis should be present upon enrollment; * The clinical severity of AD should correspond to an EASI ranging between 1.0 and 21.0 and an IGA equal to 2 or 3; * Pruritus severity assessed by means of VAS scale ≥ 4 cm) should be referred to the part of the body to be treated, as a requirement for inclusion in the study; * The clinical assessment should envisage for the patient the indication of a moisturizing/emollient treatment as single therapy for AD (in accordance with European Guidelines on AD treatment). Exclusion Criteria The following items are to be considered as exclusion criteria: * the application of cortisone-based products on the skin to be treated in the 2 weeks prior to treatment; * use of antibiotics and systemic anti-inflammatory drugs for AD in the 2 weeks preceding treatment and during the study (paracetamol is allowed at dosages and indications recommended for use as an antipyretic and analgesic); * ongoing baseline treatment (T0) with anti-inflammatory drugs, antihistamines, antitussives and/or inhaled steroids in the 2 previous weeks, retinoids and/or immunosuppressants in the previous 6 months. * use of systemic steroids in the 4 weeks prior to the study. * Intense and prolonged sun exposure in the 30 days preceding the screening. * severe AD (EASI \> 21) or mild/moderate AD requiring a local and/or systemic treatment included among treatments not allowed, as provided for in exclusion criteria; * hypersensitivity to the study products. * acute or chronic skin diseases - except for atopic eczema - which may invalidate clinical assessments or overlap with AD skin picture; * systemic diseases which may affect the subject's safety or wellbeing or interfere with skin response.